Skip to Main Content
Why Fish
Diversity, Equity & Inclusion
Pro Bono & Social Responsibility
Legal Operations
Pricing
Legal Project Management
Knowledge Management
eDiscovery
Legal Technology Services
Our People
Services
Litigation
Patent Litigation
Trademark, Copyright & Media Litigation
Trade Secret Litigation
Appellate
Standard Essential Patents
Chancery & Corporate Governance
Post-Grant
<p><em>Inter Partes </em>Review</p>
Post-Grant Review
<p><em>Ex Parte</em> Reexamination</p>
Supplemental Examination
Patent
Patent Prosecution
Strategic Patent Counseling & Opinions
Patent Portfolio Management
Unitary Patent & Unified Patent Court
IP Licensing, Transactions & Agreements
Trademark & Copyright Counseling & Prosecution
Strategic Counseling, Registration & Opinions
Advertising & Marketing
Domain Names & Internet
TTAB Oppositions & Cancellations
Digital Millennium Copyright Act
Transactions & Agreements
Regulatory & Government Affairs
Communications & Spectrum Regulation
Drug & Medical Device Regulation
mHealth & Telemedicine
Privacy & Data Security
Industries
Electrical & Computer Technology
Software & Internet
Hardware
Semiconductors
Consumer Electronics
Optics
Artificial Intelligence
Digital Health
Digital Media & E-Commerce
Financial, Business & FinTech Services
Telecommunications
Energy & Chemicals
Petrochemical
Cleantech
Life Sciences
Biotech & Diagnostics
Medical Devices
Pharmaceuticals
Academic Research & Medical Centers
Transportation, Aerospace & Defense
Manufacturing
Autonomous Vehicles
Insights
Thought Leadership
IP Law Essentials
Post-Grant Annual Reports
Webinars
Podcasts
Offices
Careers
News & Events
Contact Us
Brendan
McLaughlin
Title
Associate
Offices
Washington, D.C.
Phone Numbers
202-626-6438
Email
[email protected]
Overview
Insights
Home
People
Brendan McLaughlin
People
Insights
Additional Insights
Publications
"Using US Discovery Law to Help Satisfy Unified Patent Court Evidentiary Demands.”
Bloomberg Law
(January 2024)
"Advantages of Suing US Government for Patent Infringement Under Sec. 1498.”
Bloomberg Law
(August 2023)
"IP Rulings Show Agency Policies May Curb Appellate Review.”
Law360
(April 7, 2023)
"ITC Section 337 Investigations: 2022 Highlights and Horizon Issues.”
Practical Law Intellectual Property & Technology
(January 16, 2023)
"Potential Benefits of Adding Attorney Fee-Shifting at the ITC.”
Law360
(September 12, 2022)
"A new era at the PTAB? Director Vidal issues new guidance on discretionary denials of institution.”
Westlaw Today
(July 22, 2022)
"Is Work From Home a U.S. Venue Work-Around?”
Kluwer Patent Blog
(January 11, 2022)
"Patent Eligibility Is Becoming Increasingly Relevant at ITC.”
Law360
(November 29, 2021)
"ITC Already Has Authority Offered by Trade Secret Misuse Bill.”
Law360
(July 13, 2021)
"Bill Curtailing NPE Suits at ITC Could Restructure Licensing.”
Law360
(September 16, 2020)
"What If Gov’t Allows Patent Infringement For COVID-19 Drugs?”
Law360
(April 1, 2020)
"ITC May Be Straying From Traditional Exclusion Order Test.”
Law360
(December 17, 2019)
"Are ITC Cease and Desist Orders Overstepping Statutory Constraints?”
337 Reporter
(2018)
Monthly Contributor,
337 Reporter
Monthly Round-Up (2020-2024)
Show more
Show less